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Abstract
A recent Keystone Symposium Meeting on "Immunological Intervention in Human Disease" was
held in Big Sky, Montana on January, 6–11, 2007, organized by Jacques Banchereau, Federica Sallusto
and Robert Coffman. It brought together basic scientists and clinicians from both academia and the
pharmaceutical industry to discuss how the immune system is involved in the development of
human diseases, including cancer, allergy, autoimmunity, and infectious diseases. We highlight
advances in our understanding of the pathogenesis of immune-mediated diseases and future
approaches in the immune therapeutic interventions. Considerable progress in the development of
model systems and methodologies to monitor human immune responses will help to develop and
to evaluate new immune-based therapies at pre-clinical and clinical studies.
Introduction
Inappropriate immune responses cause a wealth of
human diseases. Insufficient immune responses are asso-
ciated with cancer or chronic infections. Conversely,
excessive or undesirable immune responses are associated
with allergy, autoimmune disease and the graft rejection
in transplantation. Animal models, particularly the use of
highly inbred and genetically-modified mouse strains,
have been instrumental in advancing our understanding
of the complex functions of the immune system in the
past decades. Nevertheless, besides vaccinations, surpris-
ingly few immunological treatments for immune-medi-
ated pathologies are currently available. Notable
exceptions include the use of monoclonal antibodies such
as TNF antagonists (anti-TNF monoclonal antibody, or
soluble TNF receptor) to treat rheumatoid arthritis and
other chronic inflammatory diseases, and anti-CD20
monoclonal antibody currently used to treat B cell lym-
phomas and certain autoimmune diseases.
The meeting emphasized the importance of directly
assessing the human immune responses, and that not all
of what we learn in the mouse can be directly translated to
humans. Importantly, one of the focuses of the meeting
was to contribute to the education of a new generation of
scientists and immunotherapists.
Recent progress in human immunology
Dendritic cells (DCs)
DCs play a key role in initiating and controlling the mag-
nitude and the quality of adaptive immune responses [1].
Immature DCs decode and integrate such signals, and
ferry this information to adaptive immune cells. The type
of adaptive immune responses is highly dependent on the
nature of the activating stimuli that DCs receive from the
microenvironment. DCs are composed of subsets. There
are two major human DC subsets, myeloid DCs (mDC)
and plasmacytoid DCs (pDC). Human myeloid DC sub-
set is further divided into two subsets, Langerhans cells
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induce immune responses (J Banchereau; Baylor Institute
for Immunology Research, TX). Langerhans cells are
potent at priming antigen-specific naïve CD8+ T cell
responses, and inducing Th1 and Th2 cell responses,
while interstitial DCs prime naïve B cells for development
into IgM secreting plasma cells and promote CD4+ T cell
differentiation towards those specialized for help of anti-
body secretion from B cells (follicular helper T cells). It
was proposed that Langerhans cells preferentially induce
cellular immunity, while interstitial DCs preferentially
drive humoral immunity (Banchereau), a concept that
might impact effective design of vaccines, particularly in
cancer and chronic infectious diseases. The second major
DC subset, pDC is specialized for secreting type I IFN.
Type I IFN secretion is impaired by the co-stimulation of
unique receptors expressed by pDCs, such as ILT7,
BDCA2, and NKp44 (Y-J Liu; MD Anderson, TX). All these
pDC receptors are associated with FcεR1γ, which deliver
strong inhibitory signals through an immunoreceptor
tyrosine-based activation motif (ITAM) (Liu) [2].
In the steady state, DCs continuously capture antigens
from dying cells, and present self-antigens to T cells,
resulting in depletion or anergy of self-reactive T cells.
Peripheral tolerance may be actively maintained by "toler-
ogenic" DCs, which induce the differentiation of T cells
with regulatory/suppressor functions. DC10, defined as
monocyte-derived DCs generated in the presence of IL-10,
promote IL-10-secreting anergic CD4+ T cells with sup-
pressive functions (T regulatory type 1, Tr1 or IL-10-Treg).
They express high levels of inhibitory immunoglobulin
like transcript (ILT) receptors, particularly ILT4, and its
ligand, HLA-G. The binding of HLA-G on T cells with ILT4
on DCs appears to be critical for the differentiation of
induction of Tr1 (S Gregori; San Raffaele Telethon Insti-
tute, Italy). In mouse spleen, CD101 was proposed as a
marker of tolerogenic DCs (J Bluestone; UCSF, CA), as
CD101-expressing CD8α- splenic DCs have capacity to
convert naïve CD4+ T cells into FoxP3+ regulatory T cells in
vitro.
T cell subsets
The most recently described subset, Th17 cells, which
preferentially secrete IL-17-family cytokines (IL-17F, IL-
22, IL-26 and CCL20) [3], is involved in autoimmune dis-
eases and acute inflammatory responses. Th17 cells also
appear to play a critical role in the protection from infec-
tion and are essential for the recovery from K. pneumoniae
infection in mice (J Kolls, Children's Hospital of Pitts-
burgh, PA).
Evidence of Th17 involvement in human diseases exists in
multiple sclerosis (C Rohowsky-Kochan, New Jersey Med-
ical School, NJ) and in psoriasis (R de Waal Malefyt;
DNAX, CA). In mice, the development of Th17 and
CD25+ Foxp3+ Treg in vitro is mutually exclusive. While
the combination of TGF-β and IL-6 drives murine T cell
differentiation towards Th17, TGF-β alone drives their dif-
ferentiation towards FoxP3+ Treg [4]. In humans, IL-1β
and IL-6 represent key factors for Th17 differentiation in
vitro, while IL-2, an essential growth factor for essentially
all other T cell populations, antagonises Th17 develop-
ment [5] (F Sallusto; Institute for Research in Biomedi-
cine, Switzerland). Due to higher capacity to secrete these
cytokines, monocytes are better than monocyte derived
DCs in supporting the generation of Th17 (Sallusto).
Other studies suggest IL-6 alone potently induces Th17
cells in vitro, IL-23 showing some additive effect
(Rohowsky-Kochan). Several rounds of stimulation with
IL-23 may be sufficient for the development of Th17
[3](de Waal Malefyt). In stark contrast to mice, TGF-β
inhibited the differentiation of Th17 cells in humans (Sal-
lusto and Rohowsky-Kochan). Human blood Th17 cells
can be identified as a CD4+ T cell subset expressing both
CCR4 and CCR6 [5] (Sallusto).
The expression of chemokine receptors controls the
migration of T cells, and allows identification of T cell
subsets with distinct functions. For example, CXCR5+
CD4+ T cells represent a unique subset in the blood, which
has potent capacity to prime naïve B cells (R Morita, Bay-
lor Institute for Immunology Research, TX). CXCR3+CD8+
T cells appear to be critical for the termination of primary
immune responses [6]. CXCR3+CD8+ T cells migrate to
reactive, but not resting, lymph nodes (LN) in response to
CXCL9, which is transiently secreted by inflammatory
high endothelial venules (HEV). CTL that have migrated
to the reactive LN then kill antigen-presenting DCs, result-
ing in inhibition of naïve CD4+ and CD8+ T cell priming
(Sallusto).
NK, NKT cells
Innate immune cells are involved in the first line of the
response to microbial infections. However, their activity is
tightly regulated by the adaptive immune system, proba-
bly to avoid excessive inflammation and host pathology.
NKR-P1A (CD161) might be involved in the regulation of
the activity of NK cells (L Lanier, UCSF, CA). LLT1, a type
II disulfide bonded homodimer with a short cytoplasmic
tail, was identified as the human ligand for NKR-PIA.
LLT1 is expressed on pDCs activated with CpG and/or
viral stimulation, and B cells stimulated with CpG or anti-
CD40/IgM Abs. Stimulation through NKR-P1A inhibits
NK cell cytotoxicity and IFNγ secretion. Thus, activated
pDCs and B cells may regulate NK cell activity at the late
stage of viral infections.
NK and NKT cells play an important role in immune sur-
veillance against tumorigenic cells, and protective immu-Page 2 of 7
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galactosyl-ceramide (αGalCer), a synthetic NKT cell lig-
and, expand an NKT cell population, both in vitro and in
vivo, that is capable of secreting large amounts of
cytokines and killing target cells. This cognate interaction
between NKT cells and DCs also leads to the potent acti-
vation of DCs, therefore NKT cells are proposed to act as
an "adjuvant" for the induction of anti-tumor immunity
in vivo (R Steinman, Rockefeller, NY). Expansion of NKT
cells and antigen-specific T cells was observed after injec-
tion of αGalCer loaded mature DC into 5 advanced cancer
patients [7] (Steinman).
Human NKT cells expressing invariant TCR recognize a
wide repertoire of ligands including both foreign and self-
glycolipids in the context of CD1d. Enormous variability
in the frequency of NKT cells exists among healthy indi-
viduals and the genetic basis for this is ascribed to the
SLAM superfamily at the level of NKT cell development in
the thymus. An endogenous NKT cell ligand, iGb3, plays
a critical role in NKT cell development (A Bendelac, Chi-
cago, MI). A study of the crystal structure of a complex of
human CD1d with αGalCer revealed the unique require-
ment of both A' and C' CD1d pocket-binding chain struc-
ture of αGalCer for the optimal stimulation of NKT cells
(V Stronge, Oxford, UK). The discovery of novel ligands
for NKT cells may lead to the identification of the optimal
ligand for use as an "adjuvant" in vaccines for cancer or
infectious diseases (A Bendelac, Chicago, MI).
Novel discoveries and therapeutic approaches in 
human diseases
Cancer
Active immunotherapy with cancer vaccine seeks to
induce therapeutic anti-tumor immunity. Tumor-specific
immune responses were successfully induced in patients
by various vaccines, however, the overall rate of clinical
response remains low. Thus, a deeper understanding of
cancer pathogenesis is critical to improve the design of
cancer vaccine.
Breast tumors attract DCs, which are modified to induce
the differentiation of T cells towards inflammatory Th2
cells. The secreted IL-13 signals cancer cells as demon-
strated by the presence of phosphorylated STAT-6 and
contributes to tumor growth as demonstrated in human-
ized mice model described hereunder [8] (K Palucka, Bay-
lor Institute for Immunology Research, TX). CXCR7, a
chemokine receptor for CXCL11 and 12, may represent
another potential target in cancer immunotherapy (B
Summers, Mountain View, CA).
Immunity against cancer stem cells may be necessary to
fully protect against cancer development and progression
(M Dhodapkar, Rockefeller, NY). Cellular immunity
against SOX2, a gene critical for self-renewal in embryonal
stem cells, appears to block the malignant transformation
of a benign monoclonal gammopathy of undetermined
significance (MGUS), into multiple myeloma [9].
Cytostatic drugs such as anthracyclins promote anti-
tumor immunity by inducing "immunogenic" tumor cell
death. Two molecules are suggested to be key parameters
in this process; calreticulin (CRT) [10], which is exposed
on the cell surface of tumour cells, and high mobility
group box 1 (HMGB-1), which is secreted by dying tumor
cells. CRT facilitates tumor antigen uptake by DCs.
HMGB-1 appears to associate with TLR4 and promote the
uptake of tumor cells rather than the activation of DC.
This observation is supported by evidence that a mutation
in TLR4 (Asp 299 Gly), which blunts NFκB activation by
HMGB-1 binding, correlates with poor survival in breast
cancer [11](L Zitvogel, France).
Vaccines targeting idiotype protein expressed by lym-
phoma cells are known to induce immunological and
durable clinical responses. Alternative strategies include
the injection of autologous DCs into the tumor following
adjuvant therapy such as radiotherapy or chemotherapy.
Injecting CpG into the tumor after radiation therapy can
further enhance anti-tumor immunity, an approach that
does not require ex-vivo cell preparation (R Levy, Stan-
ford, CA). A clinical trial for breast cancer using a MUC-1
peptide (100 mer) with adjuvant indicated the stabiliza-
tion of the disease in 20% of vaccinated patient popula-
tion (O Finn, Pittsburgh). Targeting Tregs might be an
important strategy to increase anti-tumor immunity.
Indeed, many patients with metastatic melanoma display
melanoma antigen-specific Treg in the blood (H Ueno,
Dallas, TX). These melanoma-specific Treg secrete large
amounts of IL-10, and express FoxP3 and CTLA-4.
The adoptive transfer of tumor-antigen-specific T cells rep-
resents a passive form of cancer immunotherapy. Tumor
antigen-specific CD8+ T cell lines have been generated by
transducing TCR α and β chains obtained from a T cell
clone with high avidity for tumor peptide [12]. Introduc-
tion of cysteines into the constant region of the α and β
chains facilitates preferential pairing of the transduced
TCR chains, exclusion of endogenous TCR and the
enhanced selection and expansion of tumor antigen-spe-
cific CD8+ T cells (P Greenberg, Washington, WA).
Infectious diseases
Novel vaccine strategies to HIV-mediated diseases were
discussed. One strategy is to target DCs in vivo by an anti-
DC-specific Ab conjugated to relevant antigens. In vitro,
DCs incubated with HIV gag24 coupled to anti-DEC205
mAb induced efficient activation of gag-specific CD8+ and
CD4+ T cells [13] (R Steinman). In vivo, a "prime-boost"Page 3 of 7
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by a boost with an adenoviral-vector based vaccine
(encoding subtype B Gag-Pol-Nef fusion protein, and
modified envelope (Env) constructs from subtypes A, B,
and C), was shown to enhance anti-HIV cellular and
humoral immunity (R Koup, NIH, MD). Induced HIV-
specific T cells revealed more polyfunctional responses in
HIV non-progressors than in progressors, suggesting that
the quality of induced HIV-specific T cells have a great
impact on the clinical outcome (R Koup). Another vaccine
based on conjugates of the gag protein with a TLR7/8 ago-
nist induced gag-specific CD4+ and CD8+ T cells capable of
secreting multiple effector cytokines in nonhuman pri-
mates (R Seder, NIAID, MD). Vaccines with TLR7/8 ligand
and gag without conjugation induced poor antigen-spe-
cific T cell immunity, and the secretion of fewer cytokines.
The capacity to generate effective T cell immune responses
able to stop HIV replication in vivo represents an enor-
mous clinical challenge, and T cell "exhaustion" during
HIV infection may be an important contributing factor.
PD-1 levels expressed on HIV-specific T cells correlate sig-
nificantly with viral load during chronic HIV infection
[14,15]. These PD-1+ T cells represent "exhausted" T cells,
which fail to respond to antigenic stimuli. Functional
impairment could be reversed in vitro by PD-1/PD-L1
blockade (P-R Sekaly, Montreal, Canada).
Inflammatory diseases/Autoimmune diseases
Psoriasis is a common autoimmune disease of the skin
that affects about 2–3% of Western populations. pDCs
accumulate in the inflamed skin at an early stage of the
disease, and secrete type I IFN. LL-37, a peptide secreted
from keratinocytes activates pDCs to secrete type I IFNs
and may thus offer a novel therapeutic target [16](M Gil-
liet, MD Anderson, TX). LL-37 forms a complex with
DNA, and prolongs DNA retention in early endosomes.
This induces the potent activation of pDCs through TLR9,
resulting in type I IFN secretion. mDCs at the psoriatic
lesion secrete also IL-23, and thus are contributing to the
development of Th17 cells which are involved in the
pathogenesis of psoriasis (M Gilliet; R de Waal Malefyt,
DNAX, CA). Th17 cells also promote the secretion of anti-
microbial components from keratinocytes, such as β-
defensins, which induce maturation of mDCs (R de Waal
Malefyt). Another pathogenic T cell subset in psoriasis is
VLA-1 (integrin α1β1)-expressing CD4+ T cells that accu-
mulate in the inflamed epidermis in psoriasis. Blocking
VLA-1 prevents the migration of these cells into the tissue
and inhibits the development of psoriasis, highlighting
VLA-1 as a therapeutic target for psoriasis (F Nestle, King's
College London, UK).
Systemic lupus erythematosus (SLE) is an autoimmune
disease in which antibodies are formed against several
nucleoproteins. SLE is associated with an increased pro-
duction of Type I IFNs, most likely derived from pDCs fol-
lowing activation via TLR7 or TLR9. Novel approaches
have been explored for the treatment of SLE using antago-
nists of TLR7/8/9 (G Lipford, Coley Pharmaceutical, MA)
or TLR7/9 (R Coffman, Dynavax, CA). Lupus prone-mice
receiving these antagonists generated less anti-dsDNA Ab
than controls (G Lipford, R Coffman). Furthermore, an
antagonist against TLR7/9 inhibited type I IFN secretion
from pDCs activated with live influenza or herpes simplex
virus as well as immune complexes (R Coffman).
In inflammatory bowel disease (IBD), pathogenic CD4+ T
cells express CCR9, a gut-homing chemokine receptor,
which thus represents a novel therapeutic target. The
administration of a small molecule antagonist of CCR9
reduces the disease severity in mouse models by blocking
CCR9+ T cell migration to the intestine (M Walters, Chem-
oCentryx).
High-dose intravenous γ-globulin (IVIG) therapy is a well-
established treatment for a number of immune diseases,
such as immunogenic thrombocytopenic purpura, and
Kawasaki disease. Studies in animal models demonstrate
that IVIG suppresses inflammatory macrophage functions
by signalling through inhibitory Ig receptors (FcγRIIB).
Sialylation of the Fc portion of IgG is critical for preferen-
tial binding to FcγRIIB, and the delivery of inhibitory sig-
nals [17](J Ravetch, Rockefeller, NY). A "sialic acid
switch" model was proposed: There, steady state Ab is
heavily sialylated, and thus anti-inflammatory, in order to
maintain tolerance, while newly synthesised Ab is less sia-
lylated, thus pro-inflammatory, and likely to promote the
clearance of microbes (J Ravetch, Rockefeller, NY).
The use of antibodies targeting molecules expressed on
pathogenic cells represents a recent success of immuno-
therapy. A B cell depleting therapy using anti-CD20 Ab
(Rituximab) is beneficial for non-Hodgkin lymphoma as
well as many B-cell mediated autoimmune diseases. The
combination of anti-CD20 Ab and BR3 (BAFF receptor)-
Fc chimeric protein, or anti-BR3 antibody induces a more
prominent elimination of a wide repertoire of B cells
including bone marrow plasma cells, and germinal center
B cells (A Chan, Genentech, CA). A recent clinical trial in
Type I diabetes used a non-mitogenic anti-CD3 Ab
(hOKT3γ1, Teplizumab). Teplizumab led to stabilization
of insulin production, preservation of islet function, and
elimination of pathogenic T cells. Teplizumab also
increased the frequency of distinct types of T regs, includ-
ing IL-10+IFNγ-CD4+, Foxp3+CD4+ and Foxp3+CD8+ T
cells (J Bluestone).
Nucleotide-binding oligomerization domain-Like Recep-
tor (NLR) family of proteins are involved in the regulationPage 4 of 7
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(J Tschopp, Lausanne, Switzerland). Certain NLR family
members promote the activation of pro-inflammatory
caspases within multiprotein complexes, called inflam-
masomes. Cryopyrin/NALP3, the best-characterized NLR
molecule, mediates caspase-1 activation upon binding of
muropeptides, peptidoglycan fragments derived from the
gram-positive and negative bacteria. NALP3 can also be
activated by endogenous danger signals released from
dying cells like uric acid [18]. Gout, which is induced by
the deposition of monosodium urate (MSU) in joints, is
also associated with the direct activation of NALP3 by
MSU [18]. A constitutively active form of mutated NALP3/
cryopyrin, which promotes IL-1β and IL-18 secretion by
activating caspase-1, causes a familial auto inflammatory
disease, Muckel Wells syndrome. Both diseases are rapidly
treatable with IL-1 receptor antagonist (IL-1ra; Anakinra).
The nervous system also appears to control immunity, as
shown by studies of the vagus nerve, whose stimulation
prevents shock and tissue injury. Acetylcholine secreted
from neurons directly acts on splenic macrophages, and
suppresses the LPS-induced secretion of TNF and
HMGB1. This suppression requires the α7 subunit of the
acetylcholine receptor, and its agonist suppresses the
cytokine secretion from macrophages (K Tracey, Feinstein
Institute, NY). Thus, vagus nerve stimulation or stimula-
tion with a α7 agonist could serve as a supportive general
approach for the treatment of diseases associated with
TNF, such as toxic shock and arthritis.
Allergy, transplantation, and immunodeficiencies
Many elements of the allergic reaction, including the pro-
duction of IgE antibodies and the recruitment and activa-
tion of eosinophils, depend on Type 2 cytokines, such as
IL-4, IL-5, and IL-13. TSLP, which is secreted by epithelial
cells, acts on DC resulting in the skewing of T cell
responses towards an inflammatory Th2 phenotype, char-
acterized by the secretion of high levels of Type 2
cytokines and TNF-α. IL-25, secreted from eosinophils,
further promotes inflammatory Th2 development by
TSLP-DCs. Th2 memory cells express the highest levels of
IL-25R [19](Y-J Liu, Houston, TX).
Allergen immunotherapy represents an antigen specific
treatment, but is associated with adverse effects in some
patients due to whole allergen binding to IgE. A synthetic
peptide vaccine containing the major T cell epitopes of Fel
d1, the major allergen of cats, which reduces clinical
responsiveness to cat allergen exposure in cat allergic sub-
jects, induces IL-10-secreting specific T cells, and sup-
presses proliferation of allergen-specific Th2 cells (M
Larche, Hamilton, Canada). Studies from an animal
model and humans suggest intravenous injection of low
or moderate doses of soluble peptide might induce pep-
tide-specific immunological tolerance (M Larche).
In transplantation, recipient DC may act as key initiators
of graft versus host disease (GVHD). Human LCs and der-
mal DCs undergo homeostatic proliferation in the skin
[20], and these host-derived DCs induce alloreactive effec-
tor cells. Elimination of recipient DC prior to stem cell
transplantation may be beneficial in preventing GVHD
(M Merad, Mount Sinai, NY).
Life-threatening infections in children might be due to
genetic/Mendelian factors. The herpes simplex encephalo-
myelitis (HSE) is caused in some cases by mutation of
UNC-93B, a molecule controlling TLR3, 7, 8, 9 signalling
[21](J-L Casanova, INSERM, France). This gene mutation
abrogates type I IFN secretion as well as pro-inflammatory
cytokine production upon TLR agonist ligation. Another
genetic disorder responsible for HSE is a one-point muta-
tion of TLR3, which results in impaired secretion of type-
I IFNs in response to poly I:C stimulation [22]. These find-
ings imply a novel therapeutic approach for the treatment
of HSE with Type I IFN (J-L Casanova).
Novel approaches for assessment of the human 
immune system
When considering the translation of basic research to
medicine, ensuring both safety and efficacy are critical.
Experiments performed in mice are not sufficient in this
aspect, as clearly demonstrated by the recent tragedy in a
phase I clinical trial with a super agonist anti-CD28 mAb
[23]. In that trial, all six volunteers developed a very rapid
systemic inflammatory response after the administration
of the antibody, and required intensive organ support
[23]. Thus, there is an urgent need for the development of
tools and assays to assess the human immune system, and
to predict its responses to novel therapeutic entities.
Antigen-specific immunity
Active immunotherapy aims at inducing antigen-specific
immune responses. Ultramulti-color flowcytometer has
been used to assess the frequency (magnitude) and the
type of cytokine secretion (quality) of antigen-specific
CD4+ and CD8+ T cell responses in non-human primates
vaccinated with HIV gag conjugated to TLR agonists (R
Seder), or volunteers vaccinated against HIV using the
"Prime-Boost" approach (R Koup). This methodology
lead to the conclusion that a potent HIV vaccine should
induce HIV antigen-specific CD4+ and CD8+ T cells with
the capacity to secrete several cytokines. Assessment of
antigen-specific T cell immunity also helps to understand
immune (dys)regulation in diseases. CD4+ T regs recog-
nizing a broad range of melanoma antigens (NY-ESO-1,
Survivin, TRP-1, and gp100) were identified by measuring
IL-10 secretion in PBMCs obtained form patients withPage 5 of 7
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(EPIMAX)(H Ueno).
There are fewer strategies to monitor antigen-specific B
cells. Testing supernatants of PBMCs stimulated with CpG
and IL-2 in vitro in multi-well plates for the presence of
binding and/or neutralizing pathogen-specific antibodies.
indicated that memory B cells secreting antigen-binding
antibodies are more prevalent than those secreting neu-
tralizing antibodies (A Lanzavecchia, Bellinzona, Switzer-
land).
Antigen-non-specific immunity
Gene expressing profiling of follicular lymphoma biopsy
samples showed a gene signature that negatively corre-
lated with prognosis (L Staudt, NIH). This signature
appears to be largely dependent on the presence of CD68+
macrophages. In particular, CTGF (connective tissue
growth factor) was found to be secreted by macrophages
at tumor sites. Fibrosis at the tumor sites due to CTGF acti-
vation may be associated with the poor prognosis, possi-
bly by hampering the anti-tumor immune responses
(Staudt). In contrast to SLE which displays a typical type I
IFN-mediated disease, microarray analysis of systemic
onset juvenile idiopathic arthritis (SoJIA) revealed an
important role of IL-1 in the development of the disease.
Twelve genes were determined that allow the discrimina-
tion of SoJIA patients from patients with infectious dis-
eases, SLE, or other autoimmune/inflammatory diseases
[24]. This demonstrates that blood microarray can be
used to identify diagnostic marker of disease (V Pascual,
Dallas, TX) (Pascual).
Humanized mice
Experimental therapy in humans is limited by ethical con-
siderations. Mouse models in which the human immune
system is reconstituted, termed humanized mice, are
being developed to perform pre-clinical studies, such as
analysis of the induction of human immune responses by
vaccines in vivo. In one model, injection of human CD34+
haematopoietic progenitor cells (HPC) into NOD-SCID
β2m-/- mice was followed by the adoptive transfer of
autologous T cells. This model was used to demonstrate
successful induction of flu-specific neutralizing IgM and
IgG responses and priming of peptide-specific CD8+ T cell
responses following vaccination with antigen/peptide-
loaded DCs (C I Yu and K Palucka, Dallas, TX). This
model was further developed to study the interaction
between DCs and cancer (epithelial tumors and
melanoma). Implanting human breast tumor into these
mice permitted to demonstrate the attraction of DCs at
tumor site. Migrated DCs expressed OX40L, and pro-
moted the development of inflammatory Th2 response.
IL-13 blocking resulted in partial regression of the
implanted tumors (Palucka).
A different humanized mouse model was generated by
intrahepatic injection of CD34+ HPCs into Rag2-/-γc-/-
mice (M Manz, Institute for Research in Biomedicine,
Switzerland). The mice develop de novo human T, B, and
DCs, have structured primary and secondary lymphoid
organs, and mount antigen-specific humoral and cellular
responses upon infection with EBV. Injection with
CXCR5-tropic HIV-1 virus induces severe infection in the
thymus and lymph nodes, resulting in systemic depletion
of CD4+ T cells as observed in humans. Infected cells
include CD68-expressing macrophages as well as CD4+ T
cells (M Manz, Institute for Research in Biomedicine,
Switzerland). Improved engraftment of human immune
cells into Rag2-/-γc-/- mice was demonstrated by pre-treat-
ment with clodronate to kill phagocytic cells (H Spits,
Genentech, CA). These mice develop human αβ and γδ T
cells including Treg, as well as B cells, NK cells, and DC
subsets. Generation of humanized mice with Rag-/-βc-/-
mice, where IL-7 signalling is intact, resulted in more
peripheral LNs and T cells. One of the limitations of this
model is the high turnover of human T cells in the mice,
resulting in the low number of T cells. This could be par-
tial overcome by transfecting BclxL into HPCs or co-injec-
tion of human fetal thymus and liver with HPCs. Further
improvement of the humanized mouse models may allow
us to study the full repertoire of human immune
responses in such models (H Spits, Genentech, CA).
Novel approaches to generate humanized antibodies with
a "HuMAb" mice are under investigation (S Steven,
Regeneron). Endogeneous murine antibody loci are
replaced by human transgenes, providing a powerful tool
to develop neutralizing high-affinity humanized anti-
body.
Conclusion
Overall, it was an exciting and unique meeting focusing
on translational research. Although translation of the
knowledge from mice to humans is the common desire of
scientists and the public, one must keep in mind that the
immune systems of mice and humans differ in many
aspects. Research with patients' samples is fundamental to
understand human diseases and to create novel therapies.
An infrastructure which promotes the study of human
immune system and its involvement in diseases needs to
be created by the collaboration with the translational sci-
entists, the public, and the government. Only through this
painful step, will we see a breakthrough in the treatment
of human diseases.
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